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Abstract
Purpose: To evaluate the risk and prognostic factors of post-catheterization pseudoaneurysm (PPA).
Material and methods: To identify the risk factors for PPA occurrence, clinical findings were compared between  
22 consecutive patients with radiologically confirmed PPAs (PPA group) and 300 randomly extracted patients with-
out PPA, who underwent transarterial angiography or intervention (sample group) between 1 January 2015 and 
31 March 2020. The PPA group was further divided into those treated successfully with mechanical compression 
(group A) and those requiring ultrasound-guided thrombin injection after compression failed (group B). Univariate 
and multivariate analyses were used to compare patient demographics, preoperative laboratory findings, procedure 
details, PPA diameter, and time interval between the procedure and compression between groups A and B to evaluate 
the prognostic factors of PPA.
Results: The PPA group demonstrated significantly elevated prothrombin time international normalized ratios  
(PT/INR) (odds ratio [OR]: 6.27, 95% confidence interval [CI]: 2.020-19.5; p = 0.00151) and more frequent popliteal 
access (OR: 14.2, 95% CI: 1.040-195.0; p = 0.0467) compared to the sample group, and radial access decreased the 
risk of PPA (OR: 0.382, 95% CI: 0.0148-0.987; p = 0.0468). One of the 22 PPAs resolved spontaneously, and 11 others 
(52.4%) were successfully treated by mechanical compression. An interval exceeding 24 hours between the procedure 
and compression was the only significant prognostic factor (p = 0.0281) between groups A and B.
Conclusions: Elevated PT/INR and popliteal access may predispose patients to PPA; close consideration of the site of 
access may lower the risk of refractory PPA.
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Introduction
Post-catheterization pseudoaneurysm (PPA) is an extreme-
ly rare complication that arises at the site of access after var-
ious diagnostic and interventional angiography procedures. 
Its reported incidence is 0.03-0.2% with radial access [1-3] 
and 0.3-0.7% with femoral access [2,3]. A pseudoaneurysm 
is a locally contained haematoma with arterial blood flow, 
which lacks a fibrous arterial wall and is surrounded by soft 
tissue. Clinical findings may include a pulsatile mass, local-
ized pain, swelling, and expanding haematoma. Mechani-
cal compression with ultrasound guidance is the first-line 
treatment to repair PPAs because the procedure is safe and 
cost-effective [4]. For intractable cases, thrombin injec-
tion (TI) or surgical repair can be alternatives. Reported 
risk factors for the formation of a PPA include patient age 
above 75 years, female gender, presence of infection, atrial 
fibrillation, hypertension, chronic kidney disease (CKD), 
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intraoperative use of anticoagulants, brachial rather than 
femoral approach to catheterization, multiple puncture at-
tempts, inadequate post-procedural haemostasis, and large 
sheath size [5-10]. The use of anticoagulants can compli-
cate compression repair for PPA [11]. However, there is 
disagreement about these risks and the prognostic factors 
of PPA. To evaluate the risk of PPA development and as-
sociated prognostic factors, we investigated cross-sectoral 
catheterizations performed within our cardiology, cerebro-
vascular, and radiology departments.
Material and methods
Study design
Our institutional review board approved this single-centre 
retrospective analysis. From 1 January 2015 through 
31 March 2020, 6401 transcatheter angiography pro-
cedures and/or interventions with arterial access were 
performed at our institution. These included coronary 
angiography (CAG), percutaneous coronary intervention 
(PCI), cerebral angiography, cerebral aneurysm emboli-
zation, angioplasty with/without stenting for peripheral 
arterial disease (PAD), embolization procedures including 
transcatheter arterial chemoembolization for hepatocel-
lular carcinoma, uterine fibroid embolization, bronchial 
artery embolization for haemoptysis, and transcatheter 
arterial embolization for arterial haemorrhage. Of these, 
22 consecutive PPAs in the same number of patients with 
radiological confirmation by ultrasound or computed to-
mography (CT) angiography were identified (PPA group). 
To identify the risk factors for the development of PPA, we 
compared the baseline characteristics of the PPA group 
that were thought to be associated with the incidence of 
PPA with those of a sample group of 300 randomly ex-
tracted patients without PPA who underwent transcath-
eter angiography procedures or interventions during the 
same period. The PPA group was further divided into 
those successfully treated with mechanical compression 
(group A) and those who required ultrasound-guided 
TI after failed mechanical compression (group B), and 
groups A and B were compared to determine the prog-
nostic factors of PPA.
Angiography procedure
Details of angiography procedures, such as access site, 
size of the inserted sheath, amount of intraoperative ad-
ministration of anticoagulant, and utilization of closure 
device for the access site, varied depending on the proce-
dures and departments. For CAG and most conventional 
PCIs, right radial access was the first choice. Other access 
sites, including the left radial, brachial, and femoral ar-
teries, were chosen in cases that required vascular access 
for haemodialysis in the right upper limb, occlusion of 
the right radial artery, and insertion of a large sheath. For 
procedures other than CAG and PCI, femoral access was 
the first choice; very rarely, popliteal access was chosen 
for endovascular treatment of PAD. In cases with radial 
access, after the procedure was completed, a compres-
sion band (TR BAND®; Terumo Corporation, Tokyo, Ja-
pan) was placed over the access site and left in place for 
6 hours. In cases with femoral access, AngioSeal (Terumo) 
was occasionally employed at the discretion of the sur-
geon. Patients generally received intraoperative heparin 
administration, consisting of 2000 units for CAG and ce-
rebral artery angiography and 5000 units for PCI, PAD, 
and cerebral aneurysm embolization.
Management for PPA
All PPAs were first managed by manual compression 
with or without ultrasound assistance and additional 
continuous compression using a TR BAND® or elas-
tic bandage until ultrasound confirmation the next day. 
For intractable cases, manual compression was repeated 
or TI was attempted. TI was performed by positioning 
a 23-gauge needle in the sac or neck of the PPA under 
ultrasound guidance and injecting 500 IU/ml of diluted 
thrombin (Fuji Pharma Co., Ltd., Tokyo, Japan) in a step-
wise manner utilizing a 1-mL syringe under ultrasound 
monitoring. Treatment success was evaluated with ultra-
sonography and defined as the disappearance of the vas-
cular signal into the sac of the PPA. All procedures were 
performed without conscious sedation. In patients with 
intolerable pain at the access site, local anaesthesia us-
ing 1% xylocaine was administered. All these procedures 
were performed after acquisition of the patient’s written 
informed consent.
Data collection and management
We collected data regarding patient demographics in-
cluding age, gender, body mass index (BMI), background 
disease for transcatheter arterial angiography or interven-
tion, and past medical history or treatment of hyperten-
sion (HT), dyslipidaemia (DL), diabetes mellitus (DM), 
chronic kidney disease (CKD; defined as an estimated 
glomerular filtration rate (eGFR) below 60 ml/min/1.73 
m2), haemodialysis, and atrial fibrillation (Af). Preop-
erative laboratory findings, including platelet count, 
prothrombin time international normalized ratio (PT/
INR), activated partial thromboplastin time (APTT), and 
fibrinogen levels, were compared between the groups. We 
also collected details regarding perioperative medications, 
such as single antiplatelet therapy (SAPT), dual antiplate-
let therapy (DAPT), and anticoagulant administration, 
as well as procedure details, including access site (radial, 
brachial, femoral, and popliteal arteries), inserted sheath 
size, and intraoperative heparin administration. Days of 
hospitalization and period of follow-up after the proce-
dure were also compared between the PPA and sample 
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groups. For patients with PPAs, the diameter of the aneu-
rysmal sac and neck, the time interval from the procedure 
to compression of the PPA (categorized into 0-24 and over 
24 hours), and the number of trials of mechanical com-
pression were compared between groups A and B to de-
termine the prognostic factors of PPA.
Statistical analysis
Categorical variables are presented as number of cases 
(percentage) and compared between the groups using 
Fisher’s exact test. Continuous variables are expressed as 
the mean ± standard deviation (SD). For each continu-
ous variable, we evaluated histograms and/or results of 
the Kolmogorov-Smirnov test to determine whether the 
continuous variables were normally distributed. We used 
the unpaired Student’s t-test to compare the continuous 
variables with normal distribution between the groups 
and the Mann-Whitney U test to compare the other con-
tinuous variables. Multivariable logistic regression analy-
sis was used to identify the independent risk factors of 
PPA. A p-value below 0.05 was considered statistically 
significant. All data analyses were performed using EZR 
statistical software (Saitama Medical Centre, Jichi Medical 
University, Saitama, Japan; http://www.jichi.ac.jp/saitama-
sct/SaitamaHP.files/statmedEN.html) [12].
Results
A total of 22 PPAs were identified during the study pe-
riod. Table 1 summarizes the baseline demographics, 
laboratory values, and procedure details of the PPA and 
sample groups. The sample group underwent significant-
ly more CAG and PCI procedures and less angioplasty 
or stenting for PAD, and the PPA group demonstrated 
significantly greater PT/INRs, more cases with popliteal 
access, and significantly fewer cases with radial access. 
Other characteristics, including age, gender, BMI, HT, 
DL, DM, CKD, HD, Af, platelet count, APTT, fibrino-
gen, antiplatelet therapy, SAPT, DAPT, anticoagulant 
medication, and inserted sheath size, were not significant 
predictors of PPA. The PPA group also experienced sig-
nificantly longer hospitalizations. Multivariable analysis 
demonstrated significant association between PT/INR 
above 1.5 (p = 0.00151), radial access (p = 0.0468), and 
popliteal access (p = 0.0467) and the occurrence of PPA 
(Table 2).
One of the 22 PPAs thrombosed spontaneously, 11 
were treated with mechanical compression (group A); 
and ten required TI after failed attempts at mechanical 
compression (group B). Table 3 details the demographics 
of groups A and B. The only significant prognostic factor 
of PPA (p = 0.0281) was the time interval between the end 
of the procedure and initiation of compression. Other de-
mographics, laboratory values, procedure details, sizes of 
PPAs, utilization of ultrasound guidance for compression, 
number of attempts at compression, and length of time for 
compression in each session were equal between groups 
A and B. In group B, single sessions of TI were success-
fully performed using an average dose of 525 ± 368 IU 
(range, 200-1500 IU) of thrombin. Outpatient clinical 
follow-up for the PPA group revealed no recanalization 
or complications at an average follow-up of 12.7 months 
(range, 1-41 months).
Discussion
In this investigation, the incidence of PPA was signifi-
cantly lower in patients who underwent CAG or PCI and 
radial access and significantly higher in cases with greater 
PT/INR and popliteal access. In addition, detection of 
PPA more than 24 hours after the procedure could com-
plicate mechanical compression of PPA.
In our institution, most CAG and PCI procedures are 
performed using radial access. The radial route has been 
reported to reduce access-site complications including 
PPA in coronary and non-coronary interventions [13,14], 
and our study also demonstrated a lower risk of PPA de-
velopment in a radial approach. The lower incidence of 
PPAs in patients undergoing CAG or PCI is thought to be 
attributable to the more frequent choice of radial access 
in those procedures. On the other hand, a significantly 
higher incidence of PPAs was observed in popliteal ac-
cess. Pseudoaneurysm of the popliteal artery is more com-
monly reported following a surgical operation such as to-
tal knee arthroplasty or trauma [15], and little is reported 
about the development of pseudoaneurysms following 
popliteal artery access for catheterization. Although our 
sample size is too small to derive any conclusions, this 
comparatively infrequent access site may increase the risk 
of PPA formation.
PT/INR is a widely accepted index to evaluate clot-
ting time upon activation of the extrinsic and common 
coagulation pathway and to monitor the effectiveness of 
anticoagulation therapy. PT/INR is elevated in patients 
such as those receiving warfarin therapy or lupus anti-
coagulants or with liver dysfunction, bile duct obstruc-
tion, vitamin K deficiency, coagulation factor deficien-
cies, and disseminated intravascular coagulation. Indeed, 
our study suggested an association of increased risk 
of PPA with elevated PT/INR, which was caused by an-
ticoagulant medications as well as the other conditions 
mentioned above. The presence of anticoagulant medi-
cations including warfarin therapy and heparinization, 
intraoperative administration of heparin, and APTT 
were not significant predictors of PPA. A previous re-
port suggested that PT/INR is a more reliable indicator 
of coagulopathy than APTT [16], and so PT/INR can 
be the most noteworthy parameter as a predictor of 
PPAs. This result supports the consensus guidelines for 
periprocedural management of percutaneous image-
guided interventions [13], which recommend correction 
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Table 1. Comparison of clinical characteristics between the post-catheterization pseudoaneurysm and sample groups
Variable PPA group 
(n = 22)
Sample group 
(n  = 300)
p-value
Age (years), mean ± SD 70.5 ± 11.9 68.2 ± 11.6 0.363**
Male gender, n (%) 10 (45.5) 198 (66.0) 0.065*
Body mass index (kg/m2), mean ± SD 21.9 ± 3.2 23.6 ± 4.0 0.0547**
Hypertension, n (%) 20 (90.9) 240 (80.0) 0.272*
Dyslipidaemia, n (%) 14 (63.6) 202 (67.3) 0.815*
Diabetes mellitus, n (%) 5 (22.7) 80 (26.7) 0.806*
Chronic kidney disease, n (%) 11 (50) 114 (38.0) 0.268*
Haemodialysis, n (%) 1 (4.5) 25 (8.3) 1*
Atrial fibrillation, n (%) 2 (9.1) 18 (6.0) 0.637*
Platelet count (103/µl), mean ± SD 216 ± 70 227 ± 78 0.503**
PT/INR, mean ± SD 1.38 ± 0.91 1.07 ± 0.34 0.0106***
PT/INR > 1.5 (%) 6 (27.3) 16 (5.3) 0.00213***
APTT (s), mean ± SD 43.4 ± 46.8 41.0 ± 54.0 0.841**
Fibrinogen (mg/dl), mean ± SD 334 ± 76 350 ± 87 0.468**
Medication, n (%)
Single antiplatelet therapy 3 (13.6) 55 (18.3) 0.776*
Dual antiplatelet therapy 15 (68.2) 179 (59.7) 0.504*
Anticoagulative therapy 8 (36.3) 60 (20.0) 0.0996*
Access site, n (%)
Radial 8 (36.4) 186 (62.0) 0.0233*
Brachial 2 (9.1) 21 (7.0) 0.664*
Femoral 10 (45.5) 91 (30.3) 0.156*
Popliteal 2 (9.1) 2 (0.7) 0.0246*
Sheath size (French), mean ± SD 5.23 ± 1.57 5.55 ± 0.78 0.225***
Intraoperative heparin dose (units), mean ± SD 3,050 ± 2,130 2,560 ± 1,800 0.28***
Hospitalization period (days), mean ± SD 26.0 ± 29.1 9.37 ± 12.2 < 0.01**
Follow-up period (months), mean ± SD 12.7 ± 12.9 8.91 ± 10.7 0.116**
Background, n (%)
CAG/elective PCI 8 (36.4) 198 (66.0) 0.00968*
Emergency PCI 4 (18.2) 45 (15.0) 0.757*
Cerebral embolization 3 (13.6) 21 (7.0) 0.219*
Angioplasty or stenting for PAD 4 (18.2) 15 (5.0) 0.0321*
Others 3 (13.6) 21 (7.0) 0.219*
APTT – activated partial thromboplastin time, CAG – coronary angiography, PAD – peripheral arterial disease, PCI – percutaneous coronary intervention, PPA – post-catheterization pseudo-
aneurysm, PT/INR – prothrombin time international normalized ratio, SD – standard deviation.
*Denotes p-values obtained using Fisher’s exact test. **Denotes p-values obtained using Student’s t-test. ***Denotes p-values obtained using Mann-Whitney U test
Table 2. Multivariate logistic regression analysis to assess the risk factors of post-catheterization pseudoaneurysm
Variable Odds ratio 95% CI p-value
PT/INR > 1.5 6.27 2.020-19.500 0.0015
Radial access 0.38 0.015-0.987 0.0468
Popliteal access 14.20 1.040-195.000 0.0467
PT/INR – prothrombin time international normalized ratio
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of the PT/INR to < 1.5 for procedures with moderate 
bleeding risk, such as angiography and arterial embo-
lization.
In this study, no significant difference between the 
PPA and sample groups was observed regarding other 
previously reported predisposing factors for PPA, such as 
older age, female gender, medical history of HT, CKD, or 
Af, sheath size used in the procedure, and use of brachial 
access [5-10]. Further comprehensive investigation is de-
sirable to determine the risk factors of PPA.
Table 3. Comparison of the clinical characteristics between groups A and B





Age (years), mean ± SD 75.5 ± 9.2 66.6 ± 12.6 0.0776**
Male gender, n (%) 4 (36.4) 5 (50.0) 0.67*
Body mass index (kg/m2), mean ± SD 21.7 ± 3.0 21.4 ± 2.5 0.773**
Hypertension, n (%) 10 (90.9) 9 (90.0) 1*
Dyslipidaemia, n (%) 8 (72.7) 5 (50.0) 0.387*
Diabetes mellitus, n (%) 3 (27.3) 2 (20.0) 1*
Chronic kidney disease, n (%) 7 (63.6) 4 (40.0) 0.395*
Haemodialysis, n (%) 1 (9.1) 0 (0) 1*
Atrial fibrillation, n (%) 1 (9.1) 1 (10.0) 1*
Platelet count (103/µl), mean ± SD 191 ± 49 247 ± 81 0.0661**
PT/INR, mean ± SD 1.40 ± 1.14 1.39 ± 0.69 0.974***
PT/INR > 1.5 (%) 2 (18.2) 4 (40.0) 0.361***
APTT (s), mean ± SD 51.6 ± 65.9 34.9 ± 10.5 0.438**
Fibrinogen (mg/dl), mean ± SD 325 ± 88 334 ± 14 0.854**
Medication, n (%)
Single antiplatelet therapy 0 (0) 2 (20.0) 0.214*
Dual antiplatelet therapy 10 (81.8) 5 (50.0) 0.0635*
Anticoagulative therapy 2 (18.2) 6 (60.0) 0.0805*
Access site, n (%)
Radial 2 (18.2) 5 (50.0) 0.183*
Brachial 1 (90.9) 1 (10.0) 1*
Femoral 6 (54.5) 4 (40.0) 0.67*
Popliteal 2 (18.2) 0 (0) 0.476*
Sheath size (French), mean ± SD 5.45 ± 1.57 4.90 ± 1.66 0.43***
Intraoperative heparin dose (units), mean ± SD 3.54 ± 2.11 2.30 ± 20.6 0.196***
Hospitalization period (days), mean ± SD 27.4 ± 22.0 26.6 ± 37.1 0.966**
Follow up period (months), mean ± SD 12.4 ± 11.8 10.6 ± 12.7 0.745**
Sac diameter of aneurysm (mm), mean ± SD 13.2 ± 6.4 16.2 ± 16.7 0.635**
Neck length of aneurysm (mm), mean ± SD 2.4 ± 1.0 1.9 ± 1.0 0.323***
Time interval between the procedure and compression
0-24 hours 7 (63.6) 1 (10.0) 0.0281***
Over 24 hours 4 (36.4) 9 (90.0)
Utilization of ultrasound guidance for compression 7 (63.6) 7 (70.0) 1*
Number of attempts of compression 1.1 ± 0.3 1.6 ± 0.8 0.0982***
Duration of compression in each session, minutes 36.9 ± 15.6 31.9 ± 27.3 0.203**
APTT – activated partial thromboplastin time, CAG – coronary angiography, PAD – peripheral arterial disease, PCI – percutaneous coronary intervention, PPA – post-catheterization pseudo-
aneurysm, PT/INR – prothrombin time international normalized ratio, SD – standard deviation.
*Denotes p-values obtained using Fisher’s exact test. **Denotes p-values obtained using Student’s t-test. ***Denotes p-values obtained using Mann-Whitney U test
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The reported 72-93% success rate of mechanical com-
pression can fall in cases with anticoagulation status, PPA 
size exceeding 2 cm, and obesity [11,17-19]. Generally, the 
use of compression to treat PPA is easy, cost-effective, and 
safe and yields an acceptable success rate, but it is time-
consuming and sometimes requires intravenous sedation 
because of pain during, and at the site of, compression [4]. 
Our finding of relatively lower success with mechanical 
compression for PPA (11 of 21 PPAs [52.4%]) may be at-
tributable to the absence from our compression protocol 
of a standard guideline regarding the length of time of 
compression, whether and how to employ ultrasonogra-
phy and intravenous sedation, and when to switch to TI. 
We found that detection of PPA more than 24 hours after 
the procedure can complicate repair by mechanical com-
pression, and successful repair has been associated with 
the time interval between catheter removal and compres-
sion [11]. Thus, prompt recovery from PPA requires close 
and continuous evaluation of the access site after the pro-
cedure.
Although thrombin is still unlicensed for the treatment 
of PPA, TI has been proven as a safe and reliable procedure 
for PPA, with a reported success rate of 86-98% by a di-
rectly made thrombus followed by convertion of inactive 
fibrinogen into fibrin [4,6,20]. TI is feasible even for PPAs 
after failed attempts with mechanical compression [2]. 
The injection of a diluted thrombin to 100 or 1000 IU/ml 
has been reported [4], but the optimal concentration 
remains unclear. Injection of a lower concentration of 
thrombin may increase the amount of thrombin, and use 
of a higher concentration may increase the risk of non-
targeted thrombus.  In this study, thrombin diluted to 
500 IU/ml was employed and demonstrated satisfactory 
efficacy and safety. Potential risks of TI are thrombosis in 
the native or distal arteries, allergic reactions to throm-
bin, and recanalization [6]. Although surgical repair has 
been the gold standard to treat PPA, it requires the use of 
general anaesthesia and is more expensive than TI. Hence, 
thrombin injection is a promising alternative for intrac-
table PPA.
Our study is limited by its retrospective nature, single-
centre design, relatively small population with PPAs, and 
no consideration about the difficulty and adequacy of the 
procedures involved, including puncture and haemostasis 
at the site of access.
In summary, the risk of PPA can increase in cases 
in which the PT/INR exceeds 1.5 and popliteal access is 
used, and the risk decreases with radial access. In addi-
tion, the detection of PPA more than 24 hours after the 
procedure can be a prognostic factor of ineffective me-
chanical compression of the PPA.
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